BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary cancers.

At the ESCMID Global conference in Austria, the development of climate-informed infectious disease risk management systems was discussed.

Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals for up to $558.4m.

Valneva has received marketing authorisation from the Brazilian Health Regulatory Agency for its single-dose chikungunya vaccine, Ixchiq.

J&J is projecting a $400m hit due to US tariffs in 2025, but reaffirmed its profit outlook while raising its sales forecast.

The FDA will require an additional Phase III trial for apraglutide, the company's candidate for short bowel syndrome.

Reveal Genomics and Ona Therapeutics have entered a strategic partnership to expedite the clinical development of ONA-255.

The latest trends in cell therapies indicate a growing confidence in their effectiveness, an expansion of applications beyond oncology and significant market growth potential. However, the industry ...

Concerns over a potential US recession this year are growing as investors assess the impact of Trump's tariff policies.

Sandoz is suing Amgen over alleged patent abuse delaying the US launch of a biosimilar to the autoimmune drug Enbrel.

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.